Dougados M - Search Results

1

Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.

Benhamou M, Gossec L, Dougados M. Benhamou M, et al. Among authors: dougados m. Rheumatology (Oxford). 2010 Mar;49(3):536-41. doi: 10.1093/rheumatology/kep393. Epub 2009 Dec 22. Rheumatology (Oxford). 2010. PMID: 20028728 Clinical Trial.

2

Evaluation of a functional index and an articular index in ankylosing spondylitis.

Dougados M, Gueguen A, Nakache JP, Nguyen M, Mery C, Amor B. Dougados M, et al. J Rheumatol. 1988 Feb;15(2):302-7. J Rheumatol. 1988. PMID: 3283358 Clinical Trial.

3

Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study.

Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, Gomeni C. Dougados M, et al. Scand J Rheumatol. 1994;23(5):243-8. doi: 10.3109/03009749409103723. Scand J Rheumatol. 1994. PMID: 7973477 Clinical Trial.

4

Arthroscopic evaluation of chondropathy in osteoarthritis of the knee.

Ayral X, Dougados M, Listrat V, Bonvarlet JP, Simonnet J, Amor B. Ayral X, et al. Among authors: dougados m. J Rheumatol. 1996 Apr;23(4):698-706. J Rheumatol. 1996. PMID: 8730130

5

Prolonged effects of 3 week therapy in a spa resort on lumbar spine, knee and hip osteoarthritis: follow-up after 6 months. A randomized controlled trial.

Nguyen M, Revel M, Dougados M. Nguyen M, et al. Among authors: dougados m. Br J Rheumatol. 1997 Jan;36(1):77-81. doi: 10.1093/rheumatology/36.1.77. Br J Rheumatol. 1997. PMID: 9117181 Clinical Trial.

6

Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV.

van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. van der Heijde D, et al. Among authors: dougados m. J Rheumatol. 1999 Apr;26(4):945-7. J Rheumatol. 1999. PMID: 10229424 No abstract available.

7

Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis.

Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, Calin A. Dougados M, et al. J Rheumatol. 1999 Apr;26(4):971-4. J Rheumatol. 1999. PMID: 10229430 Clinical Trial.

8

Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.

Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Calin A, et al. Among authors: dougados m. J Rheumatol. 1999 Apr;26(4):975-9. J Rheumatol. 1999. PMID: 10229431 Clinical Trial.

9

Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S. Spoorenberg A, et al. Among authors: dougados m. J Rheumatol. 1999 Apr;26(4):980-4. J Rheumatol. 1999. PMID: 10229432

10

Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.

Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, Calin A. Dougados M, et al. Rheumatology (Oxford). 1999 Mar;38(3):235-44. doi: 10.1093/rheumatology/38.3.235. Rheumatology (Oxford). 1999. PMID: 10325662 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,130 results

Search Page

Filters